Softlax
Softlax Uses, Dosage, Side Effects, Food Interaction and all others data.
Softlax is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years .
Sodium picosulfate is a stimulant laxative that in conjunction with magnesium citrate, produces a purgative effect on stools. In a multicentre, observational study comprising of patients undergoing colonoscopy, more than 93.0% of the patients receiving sodium picosulfate-containing preparations reported the colon cleansing effect to be effective .
| Trade Name | Softlax |
| Generic | Picosulfuric acid |
| Picosulfuric acid Other Names | Picosulfate, Picosulphate |
| Weight | 7.5mg/ml |
| Type | Drops |
| Formula | C18H15NO8S2 |
| Weight | Average: 437.44 Monoisotopic: 437.023908795 |
| Protein binding | No pharmacokinetic data is available for picosulfuric acid. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Rasco Pharma |
| Available Country | Pakistan |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Softlax is a stimulant laxative used for cleansing of the colon as a preparation for colonoscopy in adults.
Indicated for cleansing of the colon as a preparation for colonoscopy in adults .
Softlax is also used to associated treatment for these conditions: Constipation, Bowel preparation therapy, Laxative
How Softlax works
Softlax, as sodium picosulfate, is a contact laxative. Sodium picosulfate inhibits the absorption of water and electrolytes, and increases their secretion into the intestinal lumen . It is hydrolyzed by colonic bacterial enzyme, sulfatase , to form an active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM), which acts directly on the colonic mucosa to stimulate colonic peristalsis .
Toxicity
Overdosage of laxative preparations containing sodium picosulfate may lead to severe electrolyte disturbances, in addition to dehydration and hypovolemia, with signs and symptoms of these disturbances. In case of overdose, monitor for fluid and electrolyte disturbances with symptomatic treatment . In vitro, 800 and 1600 mg/mL of sodium picosulfate exerted cytotoxic effects on cultured liver cells by inducing dose-dependent vacuolic and fatty change, as well as necrosis combined with a lowered mitotic activity and a slight increase in LDH values of the rapidly growing cultured liver cells of rabbit .
Food Interaction
- Avoid alcohol.
- Avoid solid foods. When using picosulfuric acid in preparation for a colonoscopy, only consume clear fluids the day before the procedure.
Volume of Distribution
No pharmacokinetic data is available for picosulfuric acid.
Elimination Route
In healthy volunteers receiving 2 packets of sodium picosulfate in combination with magnesium oxide and anhydrous citric acid every 6 hours, the mean peak plasma concentrations (Cmax) of sodium picosulfate was achieved within 7 hours (Tmax) . The mean Cmax of its active metabolite, BHPM, was 0.05 ng/mL .
Half Life
The terminal half-life of sodium picosulfate was 7.4 hours .
Clearance
No pharmacokinetic data is available for picosulfuric acid.
Elimination Route
Sodium picosulfate and its metabolite BHPM are mainly excreted in urine. The fraction of the absorbed sodium picosulfate dose excreted in urine as unchanged parent compound was 0.19% . Urinary recovery of BHPM was 0.01% of total administered drug . A small amount absorbed picosulfate is reported to be excreted in the urine as a glucuronide-conjugate of BHPM .
Innovators Monograph
You find simplified version here Softlax
